ID: ALA4864800

Max Phase: Preclinical

Molecular Formula: C13H14FN3O

Molecular Weight: 247.27

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  O=c1cc(N2CCNCC2)c2cc(F)ccc2[nH]1

Standard InChI:  InChI=1S/C13H14FN3O/c14-9-1-2-11-10(7-9)12(8-13(18)16-11)17-5-3-15-4-6-17/h1-2,7-8,15H,3-6H2,(H,16,18)

Standard InChI Key:  ODPIHPCCOSWGME-UHFFFAOYSA-N

Associated Targets(Human)

EKVX 44102 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDA-MB-435 38290 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A498 42825 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Hs-578T 29457 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

T47D 39041 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Vascular endothelial growth factor receptor 2 20924 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 247.27Molecular Weight (Monoisotopic): 247.1121AlogP: 1.08#Rotatable Bonds: 1
Polar Surface Area: 48.13Molecular Species: BASEHBA: 3HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.64CX Basic pKa: 8.93CX LogP: 0.63CX LogD: -0.91
Aromatic Rings: 2Heavy Atoms: 18QED Weighted: 0.79Np Likeness Score: -1.09

References

1. Hassan A, Badr M, Hassan HA, Abdelhamid D, Abuo-Rahma GEA..  (2021)  Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition.,  40  [PMID:33962153] [10.1016/j.bmc.2021.116168]

Source